<DOC>
	<DOCNO>NCT02964065</DOCNO>
	<brief_summary>This study Multicenter , Randomized , Double-Blind , Placebo-Controlled , Phase Ⅲ Trial evaluate efficacy , safety immunogenicity single dose Live-Attenuated influenza Vaccine ( LAIV ) among healthy child adolescent age 3-17 year .</brief_summary>
	<brief_title>A Trial Efficacy , Safety Immunogenicity Live-Attenuated Influenza Vaccine ( LAIV )</brief_title>
	<detailed_description>This study Multicenter , Randomized , Double-Blind , Placebo-Controlled , Phase Ⅲ Trial evaluate efficacy , safety immunogenicity single dose Live-Attenuated influenza Vaccine ( LAIV ) among healthy child adolescent age 3-17 year old . The subject randomize 1:1 ratio LAIV placebo . Each subject vaccinate single dose LAIV Placebo . For evaluation efficacy , subject meet protocol-defined clinical case definition 14th day post-vaccination nasal swab collect test RT-PCR virus culture evidence influenza virus infection . All adverse event collect 30 minute , 0-30 day vaccination serious adverse event entire trial period . Blood sample collect part subject vaccination 30th day immunization . Serum sample centrifuge detection antibody H1N1 , H3N2 , influenza B .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy child adolescent age 317 year old . 2 . Informed consent obtain sign subject legal guardian prior screen . Children adolescent age 1017 yr need sign inform consent . 3 . Willing participate plan duration study , include availability followup . 1 . Any investigational unregistered product ( drug , vaccine device ) use within 30 day , plan use trial . 2. vaccinated influenza vaccine within 6 month , plan vaccinate trail . 3 . Immunosuppressive agent immunomodulatory drug ( define continuous use 14 day ) use 3month period . 4 . Immunoglobulins / blood product use within 3 month , plan use blood collection . 5 . History GuillainBarré syndrome ; History hypersensitivity component LAIV , include egg egg product . 6 . Severe allergic reaction vaccination ( include anaphylactic shock , allergic laryngeal edema , allergic purpura , local allergic necrosis ) . 7 . Acute disease , infection febrile disease ( axillary temperature ≥37.1℃ ) day vaccination . 8 . Obvious coagulation dysfunction History anticoagulant therapy 9 . Aspirin use ( Salicylates potential risk factor Reye syndrome ) 10 . Known suspected immune deficiency disease immunosuppressed 11 . Heart disease , respiratory disease ( include severe rhinitis , nasal deformity , polyp , etc . ) , liver disease , kidney disease , mental disorder , chronic infection etc .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Influenza Vaccines</keyword>
	<keyword>LAIV</keyword>
</DOC>